-
CAR-NK: Human's new weapon against tumor
Time of Update: 2021-11-14
Current status of CAR-NK cell therapy The CAR-NK products designed and developed based on the CAR-T strategy are designed to target different tumors so that NK cells can specifically kill tumor cells, and different designs are designed for hematomas and solid tumors.
-
Go for a high score and take a look: 10+ ideas are offered with both hands
Time of Update: 2021-11-14
A few days ago, I shared a 13-point pure life letter article for everyone. I don't know if you feel that you are still not enough after reading it . Today, the editor once again shared a 10+ pure l
-
One article summary: Targeted therapy and immunotherapy for metastatic castration-resistant prostate cancer
Time of Update: 2021-11-14
The results showed that compared with the control group, the olaparib group could significantly improve the median radiological progression-free survival (rPFS) of cohort A patients.
The TheraP Phase II TheraP study included patients with mCRPC who had progressed in docetaxel and AR inhibitor treatment, and were randomly assigned to receive [¹⁷⁷Lu]Lu-PSMA-617 or cabazitaxel treatment .
-
Professor Yin Yongmei: Analysis of the mystery of breast cancer genes in the era of precision treatment
Time of Update: 2021-11-14
Prove the efficacy of gBRCA1/2 germline mutation/HER2-negative advanced breast cancer patients, the PARP inhibitor olaparib is better than chemotherapy, the objective response rate (ORR) reaches 60%, and the median progression-free survival (PFS) is extended to 7 months, reduce the risk of disease progression or death by 42% .
-
Progress in the treatment of acute myeloid leukemia with antibody drugs
Time of Update: 2021-11-14
Currently, research on bispecific antibody drugs targeting multiple antigens on AML cells is underway .
In clinical trials, bispecific antibodies and ADCs targeting multiple antigens on the surface of AML cells have shown significant therapeutic effects .
-
How to standardize systemic treatment of breast cancer?
Time of Update: 2021-11-14
Among them, the "Guidelines for Systemic Treatment of Breast Cancer" provide a detailed description of chemotherapy, endocrine therapy, anti-HER2 therapy, and whether to choose and use intensive therapy .
Systemic treatments after breast cancer surgery include chemotherapy, endocrine therapy, and anti-HER2 therapy .
-
The Lancet: Real-world data shows that HPV vaccine significantly reduces the incidence of cervical cancer
Time of Update: 2021-11-14
The study compared the incidence of cervical cancer and precancerous lesions before and after the start of the HPV vaccination program in the United Kingdom in 2008, and found that HPV vaccination led to a sharp decline in the incidence of cervical cancer and precancerous lesions, especially among young women In .
-
Express bicyclic peptide-coupled immunotherapy, a new solid tumor targeting model has entered the clinic
Time of Update: 2021-11-14
▎Editor of WuXi AppTec's content team Today, Bicycle Therapeutics announced that its tumor-targeted immune cell agonist BT7480, designed based on bicyclic peptides, has completed the first patient administration in a phase 1/2 clinical trial .
-
PD-L1 inhibitors that can be injected subcutaneously are about to be approved; Chinese original breast cancer "Lord of the Rings" is coming to tumor information
Time of Update: 2021-11-14
This study reports the interim results of DAWNA-1 (NCT03927456), a double-blind, randomized, phase III trial that evaluated dapicillide in hormone receptor-positive and HER2-negative ABC patients with disease progression after endocrine therapy ( The efficacy and safety of a CDK4/6 inhibitor) combined with Fulvestrant .
-
[Science Sub-Journal] A cheap oral drug-arginine, can enhance the effect of cancer radiotherapy?
Time of Update: 2021-11-14
Roffo Cancer Institute showed that treatment with arginine (an amino acid building block of protein) can enhance patients with cancer brain metastases The effectiveness of radiotherapy .
-
Classic Collection Plus: A Sign of Cancer (2)
Time of Update: 2021-11-14
Taking the RAS-RAF pathway as an example, the combination of growth factors and transmembrane receptors causes intracellular GRB2 to bind to SOS, stimulates the release of ATP from RAS protein, and the downstream Raf cascade activates MAPKKK-MAPKK-MAPK to promote transcription regulation.
-
Significant progress in cancer vaccines!
Time of Update: 2021-11-13
In this study, the researchers used the molecular model of pathogens to functionally modify low-temperature silicified tumor cells and developed an efficient method for preparing cancer vaccines .
-
Solid tumor CAR-T upgraded version: ITS-T cell therapy
Time of Update: 2021-11-13
In vitro, the PD1:CD28 chimeric molecule has been shown to respond to tumor cells expressing PD-L1 and transduce activation signals through the chimeric receptor to enhance the proliferation, cytokine production and cytotoxicity of CD8+ T cells .
-
Sadness is always inevitable?
Time of Update: 2021-11-13
Table 5 calculates the correlation between the dose variables, indicating that there is a negative correlation between the MHD, the maximum cardiac dose, and the average LAD dose in patients with right BC .
-
The country has officially issued a notice, confirming the increase!
Time of Update: 2021-11-13
Other matters For the projects that have been approved , the related fund management and expenditures will be implemented in accordance with the original policy, and no adjustments will be made .
-
Molecular Oncology Long Weiwen/Liu Jian discovered ERK3 as an oncoprotein that promotes the development and progression of lung adenocarcinoma
Time of Update: 2021-11-13
On October 31, 2021, Wright State University's Long Weiwen research team and researcher Liu Jian from Zhejiang University Edinburgh University Joint College (ZJE) jointly published a titled "Conditional ERK3 overexpression cooperates with PTEN deletion to promotelung adenocarcinoma formation in mice" in Molecular Oncology.
-
Can patients who are eligible for NDMM transplantation benefit from VRD consolidation therapy?
Time of Update: 2021-11-13
001); the patients who were randomly assigned to the MRD-negative and positive MRD groups received the consolidation treatment group from The median PFS at the start of maintenance treatment was 70.
-
Professor Changlin Zhao: How to diagnose Lynch syndrome/Lynch syndrome-related tumors?
Time of Update: 2021-11-13
Germline mutations in the MMR gene can also cause LS-related tumors (including colorectal, endometrium, ovary, stomach, small intestine, liver and gallbladder, urinary tract, brain and skin, etc.
-
How can people who never smoke get lung cancer?
Time of Update: 2021-11-13
For each subtype in LUAD, the study reconstructed the possible timing of genomic abnormalities including SCNAs, WGD and common driver genes (Figure 6) .
-
JCO: The prognosis of stage 3 gefitinib vs. cisplatin + vinorelbine for adjuvant treatment of non-small cell lung cancer after surgical resection
Time of Update: 2021-11-13
Although cisplatin-based adjuvant chemotherapy is the standard treatment for stage II and stage III non-small cell lung cancer ( NSCLC ) that are completely resected by surgery , the survival prognosis of patients is not satisfactory .
